These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 11365712)
21. A new HAART on the horizon says the proof is in the potency. AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218 [TBL] [Abstract][Full Text] [Related]
22. New expanded access drugs for use in combination therapy. Newsline People AIDS Coalit N Y; 1998 Dec; ():22-3. PubMed ID: 11367085 [TBL] [Abstract][Full Text] [Related]
23. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
24. Amprenavir study results released. AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545 [No Abstract] [Full Text] [Related]
25. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks. Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478 [No Abstract] [Full Text] [Related]
27. New drugs: amprenavir and abacavir. TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435 [TBL] [Abstract][Full Text] [Related]
29. New expanded access drugs for use in combination therapy. Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823 [TBL] [Abstract][Full Text] [Related]
30. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H; AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950 [TBL] [Abstract][Full Text] [Related]
31. Treatment of the naive patient. Bartlett JG Hopkins HIV Rep; 1999 Mar; 11(2):1, 10-1. PubMed ID: 11366244 [TBL] [Abstract][Full Text] [Related]
33. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Castillo SA; Hernandez JE; Brothers CH Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966 [TBL] [Abstract][Full Text] [Related]
34. Options when HIV treatments fail. Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426 [TBL] [Abstract][Full Text] [Related]
40. Moving forward: a treatment overview from the 12th World AIDS Conference. Agosto M Newsline People AIDS Coalit N Y; 1998 Sep; ():6-11. PubMed ID: 11367497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]